Back to Search
Start Over
Efficacy of sodium-glucose cotransporter 2 inhibitor with glucagon-like peptide-1 receptor agonist for the glycemic control of a patient with Prader-Willi syndrome: a case report
Efficacy of sodium-glucose cotransporter 2 inhibitor with glucagon-like peptide-1 receptor agonist for the glycemic control of a patient with Prader-Willi syndrome: a case report
- Source :
- Clinical Pediatric Endocrinology
- Publication Year :
- 2020
- Publisher :
- Japanese Society for Pediatric Endocrinology, 2020.
-
Abstract
- Prader-Willi syndrome (PWS) is often related to severe obesity and diabetes mellitus (DM). Clinical findings suggesting the benefits of glucagon-like peptide-1 (GLP-1) receptor agonists for glycemic control of DM in PWS have been recently increasing. However, there are only a few reports describing the effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors for PWS. We present a diabetic female with PWS, whose glycemic control was deteriorated at the age of 19 but improved to a certain extent by introducing the GLP-1 analog liraglutide. At the age of 20, the SGLT2 inhibitor empagliflozin was administered. Subsequently, her HbA1c level and body weight markedly decreased. Improvement in both insulin resistance and secretion was observed during the subsequent six months. In addition to GLP-1 receptor agonists, SGLT2 inhibitors may be a potential approach for the management of DM in PWS, especially in young patients whose pancreatic insulin secretion capabilities are still preserved.
- Subjects :
- congenital, hereditary, and neonatal diseases and abnormalities
medicine.medical_specialty
Endocrinology, Diabetes and Metabolism
Case Report
030209 endocrinology & metabolism
sodium-glucose cotransporter 2 inhibitors
03 medical and health sciences
0302 clinical medicine
Endocrinology
Insulin resistance
Diabetes mellitus
Internal medicine
medicine
Empagliflozin
030212 general & internal medicine
Receptor
Glucagon-like peptide 1 receptor
Glycemic
glucagon-like peptide-1 receptor agonists
business.industry
Liraglutide
nutritional and metabolic diseases
medicine.disease
nervous system diseases
diabetes mellitus
Pediatrics, Perinatology and Child Health
Prader-Willi syndrome
SGLT2 Inhibitor
business
medicine.drug
Subjects
Details
- ISSN :
- 13477358 and 09185739
- Volume :
- 29
- Database :
- OpenAIRE
- Journal :
- Clinical Pediatric Endocrinology
- Accession number :
- edsair.doi.dedup.....6da0376a95b65f9206054b0f160e2072
- Full Text :
- https://doi.org/10.1297/cpe.29.81